BioCryst Pharma (BCRX) Shares Ramp to Session Highs Amid Upcoming Galidesivir Data Presentation
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
BioCryst Pharma (NASDAQ: BCRX) shares are ramping to session highs after the company announced that results from a study of galidesivir (formerly BCX4430) administered to Rhesus monkeys infected with Zika virus (ZIKV) will be presented as a late-breaker oral presentation at IDWeek 2016 taking place in New Orleans October 26-30, 2016.
The stock is up around 1.7 percent.
For more color on the announcement, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neovasc (NVCN) Climbs to Session High, Shares Up 125%
- Hilton (HLT) volatility flat as shares rally into investor day
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesMomentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!